Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|June 13, 2014
An Analysis of IPMN and Pancreatic Cancer Outcomes
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer.
Advertisement
Clinical Pearls
Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of IPMN and pancreatic cancer.
- This analysis looked at the outcomes of patients with IPMN in the background of pancreatic cancer.
- It has been known that patients with IPMN do better than those with pancreatic cancer.
- Researchers hope that this data can help to identify and stratify patients to improve outcomes.
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5